Real-World Study on How Belimumab Affects Major Organ Involvement in Systemic Lupus Erythematosus Compared to Standard Treatments
Led by Biomedical Research Foundation, Academy of Athens · Updated on 2025-09-08
684
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the impact of belimumab on the natural progression of Systemic Lupus Erythematosus SLE, focusing on major organ involvement defined by BILAG A flares. This observational study compares patients receiving belimumab to two standard-of-care groups, including a historical cohort before belimumab was available in Greece. The study uses advanced statistical methods like propensity score matching to balance groups and reduce bias.
The study includes three groups patients treated with belimumab Group A, patients receiving standard-of-care treatment after May 1st, 2014 Group B, and a historical group treated with standard-of-care before that date Group C. Researchers will analyze real-world data over an expected follow-up of 1 to 4 years. They aim to understand if belimumab reduces the incidence of new major organ disease events compared to standard treatments.
Participants will have their disease activity and damage assessed over time using measures such as BILAG A flares and the SLICCACR Damage Index. The study involves reviewing clinical records and tracking disease flares and damage accrual throughout the follow-up. The research is sponsored by the Biomedical Research Foundation, Academy of Athens, and will include adults with active SLE monitored for at least six months.
CONDITIONS
Brief Title
Does Belimumab Modify the Natural History of SLE? A Propensity Score-matched, Real-world Study
Research Team
D
Dimitrios T. Boumpas, Professor in Medicine
A
Antonis Fanouriakis, Ass. Professor in Medicine
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study.
Myrto Nikoloudaki, Dionysis Nikolopoulos, Sofia Koutsoviti...
Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.
Antonis Fanouriakis, Christina Adamichou, Sofia Koutsoviti...